Form 4: Elanco CEO Jeffrey Simmons Reports Changes in Beneficial Ownership

Elanco Animal Health Inc. CEO Jeffrey Simmons reports acquisition and disposal of common stock, resulting in adjustments to his direct and indirect beneficial ownership.

Summary

• On February 27, 2024, Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., reported changes in his beneficial ownership of Elanco's common stock.
• He acquired 148,084 shares of common stock at $0.
• He disposed of 64,527 shares of common stock at $16.46.
• Following these transactions, Simmons directly owns 1,228,742 shares and indirectly owns 45,000 shares through a revocable trust.
• The direct holdings include shares acquired through Elanco's Employee Stock Purchase Plan on March 31, 2023 (2,000 shares) and June 30, 2023 (616 shares).

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without providing explicit positive or negative outlook. The acquisition and disposal of shares offset each other to some extent.

Positives

• The acquisition of shares by the CEO could be interpreted as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of shares by the CEO could be interpreted as a negative signal, indicating a lack of confidence in the company's future performance.

Risks

• Changes in beneficial ownership by company insiders can sometimes be perceived negatively by investors if the disposal of shares is seen as a lack of confidence in the company's prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Elanco's stock.

Key Dates